Latest filing published 01 Apr 2026 for EXELON CORP, €38k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Anna Richo across 3 companies, led by Exelon Corp, Adamas Pharmaceuticals Inc and Illumina, Inc. In total, 15 filings cover trades dated from 2 June 2021 to 31 March 2026.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The record was last updated on 1 April 2026 with a share grant (€38k) in Exelon Corp. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 of 15 declarations